BacteriologyA multiplex PCR/LDR assay for simultaneous detection and identification of the NIAID category B bacterial food and water-borne pathogens☆
Introduction
Enteric pathogens that cause gastroenteritis remain a major global health concern and are 1 of the top infectious causes of morbidity and mortality worldwide (Cunningham et al., 2010, de Boer et al., 2010, Gomez-Duarte et al., 2009, Nguyen et al., 2005, O'Leary et al., 2009). Infectious gastroenteritis is responsible for 1.7–2.5 million deaths annually, mostly of children under 5 years of age in developing countries (Gomez-Duarte et al., 2009, Kosek et al., 2003, Kosek et al., 2009, Liu et al., 2011, UN, 2005, WHO, 2011). In light of major global infectious disease emergencies, such as the cholera epidemic in Haiti and the highly virulent Escherichia coli outbreak across Europe, enteric bacterial pathogens remain a significant public health threat in both the developed and developing parts of the world (Askar et al., 2011, Enserink, 2011, Walton and Ivers, 2011, Nature News, 2011). Conventional diagnostic procedures for routine detection of enteric bacterial pathogens entail enrichment steps, selective culture, biochemical identification, serotyping, and/or resistance profiling. The steps for pathogen identification are laborious and time consuming, often taking 3–5 days for a final result. Several pathogens are indistinguishable from normal flora by morphology and biochemical properties. Other pathogens are difficult to culture while some have limited viability outside the host (Cunningham et al., 2010, de Boer et al., 2010, Schuurman et al., 2007). Molecular methods, including TaqMan assays or antigen detection tests, offer more rapid and sensitive detection than conventional culture methods (Gomez-Duarte et al., 2009, Liu et al., 2011, O'Leary et al., 2009). However, these molecular methods are limited in scope and scale for both the number of samples processed annually and the broad and wide-ranging number of possible pathogens that can be detected.
We have developed, characterized, and applied a high-throughput multiplex molecular assay for the simultaneous detection of Campylobacter spp. (Campylobacter jejuni, Campylobacter coli, Campylobacter lari, Campylobacter fetus, Campylobacter upsaliensis), Vibrio spp. (Vibrio cholerae, Vibrio mimicus, Vibrio parahaemolyticus, Vibrio fluvialis, Vibrio furnissii, Vibrio metschnikovii, Vibrio hollisae), enteropathogenic E. coli (EPEC), enterotoxigenic E. coli (ETEC), Shiga toxin-producing E. coli (STEC), enteroaggregative E. coli (EAEC), enteroinvasive E. coli (EIEC), diffusely adherent E. coli (DAEC), Shigella spp. (Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Shigella boydii), Salmonella spp. (Salmonella typhi, Salmonella typhimurium, Salmonella paratyphi, Salmonella arizoniae, Salmonella cholerasuis), Listeria monocytogenes, and Yersinia enterocolitica. This assay can detect and identify over 29 species of enteropathogenic bacteria across 7 different genera in a single assay protocol. Additionally, we applied this assay to clinically significant culture-positive samples for V. cholerae obtained from our international study site, the Groupe Haitien d’Etude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO) in Port-au-Prince, Haiti. Currently, this multiplex assay is the only comprehensive molecular test reported to date for the detection of all category B bacterial food and water-borne pathogens.
Section snippets
Bacterial isolates and clinical specimens
Clinical isolates from stool and other clinical specimens that had been previously phenotypically identified using conventional microbiological techniques were obtained from the clinical microbiology laboratory at New York-Presbyterian Hospital/Weill Cornell Medical Center (NYPH/WCMC) and the New York City Department of Health. Molecularly characterized isolates of diarrheagenic E. coli were kindly provided by Dr Lee Riley of the University of California Berkeley. Pure cultures of the following
Analytical sensitivity and specificity of the PCR/LDR assay with clinical isolates
The analytical specificity of the assay was 100% for pure cultures of all 97 clinical isolates. There were no false positives when testing each pure culture isolate with the PCR/LDR assay, indicating no cross-reaction between the 51 PCR primers and 157 LDR primers. We determined the limit of detection of our assay on seeded specimens to range from 101 CFU/mL to 105 CFU/mL. The concentration in which all pathogens were detected was 105 CFU/mL.
Diagnostic sensitivity and specificity of PCR/LDR with seeded specimens
The diagnostic sensitivity and specificity of the
Discussion
In this study, we describe the development and application of a multiplex PCR/LDR assay for the identification of all NIAID category B bacterial food and water-borne pathogens. The assay was designed to PCR amplify 17 genetic targets attributed to a panel of 29 pathogenic bacterial species. Species-specific single base variants within these PCR amplicons are then queried using LDR primer pairs that generate ligation products that are subsequently hybridized to their discrete individual VeraCode
Acknowledgments
We thank Stephen Jenkins, Audrey Schuetz, and the technical staff of the clinical microbiology laboratory at NYPH/WCMC for collecting and providing clinical isolates and specimens and Bill Pape at GHESKIO for his advice and support. We thank Jianmin Huang for providing the AK16D ligase enzyme. We acknowledge Lee Riley of the University of California Berkeley and the New York City Department of Health for providing us with clinical isolates.
References (22)
- et al.
Detection of Escherichia coli, Salmonella spp., Shigella spp., Yersinia enterocolitica, Vibrio cholerae, and Campylobacter spp. enteropathogens by 3-reaction multiplex polymerase chain reaction
Diagn Microbiol Infect Dis
(2009) - et al.
Fecal collection, ambient preservation, and DNA extraction for PCR amplification of bacterial and human markers from human feces
J Microbiol Methods
(2008) - et al.
Update on the ongoing outbreak of haemolytic uraemic syndrome due to Shiga toxin-producing Escherichia coli (STEC) serotype O104, Germany
Euro Surveill
(2011) - et al.
Modular microfluidic system fabricated in thermoplastics for the strain-specific detection of bacterial pathogens
Lab Chip
(2012) - et al.
Three-hour molecular detection of Campylobacter, Salmonella, Yersinia, and Shigella species in feces with accuracy as high as that of culture
J Clin Microbiol
(2010) - et al.
Improved detection of five major gastrointestinal pathogens by use of a molecular screening approach
J Clin Microbiol
(2010) Haiti's cholera outbreak. Cholera linked to U.N. forces, but questions remain
Science
(2011)- et al.
The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000
Bull World Health Organ
(2003) - et al.
Directing diarrhoeal disease research towards disease-burden reduction
J Health Popul Nutr
(2009) - et al.
Simultaneous detection of six diarrhea-causing bacterial pathogens with an in-house PCR-Luminex assay
J Clin Microbiol
(2011)
A laboratory-developed TaqMan array card for simultaneous detection of 19 enteropathogens
J Clin Microbiol
Cited by (13)
Bacterial gastroenteritis
2019, Gastrointestinal Diseases and Their Associated InfectionsDevelopment of a gold nanoparticle-based universal oligonucleotide microarray for multiplex and low-cost detection of foodborne pathogens
2017, International Journal of Food MicrobiologyCitation Excerpt :The novel tool could generate enough single stranded GNP-labeled targets for microarray detection, and is especially suitable for testing actual food samples with low levels of pathogenic bacteria. Using the developed assay, as low as 3.3–85 CFU/mL of pure cultures of the eight pathogens could be specifically detected, which is comparable to detection sensitivities of the highly sensitive quantum dots-based oligonucleotide microarray assay (10 CFU/mL of pure culture) (Huang et al., 2014), and more sensitive than the multiplex PCR-based magnetic nanoparticles microarray assay (316 CFU/mL for Salmonella enterica) (Li et al., 2013) and the multiplex PCR/LDR based universal microarray assay (105 CFU/mL) (Rundell et al., 2014). The developed GUMA was preliminarily applied to test 95 mock-contaminated and retail food samples, and results corroborated traditional culture and real-time PCR data.
Advances in ligase chain reaction and ligation-based amplifications for genotyping assays: Detection and applications
2017, Mutation Research - Reviews in Mutation ResearchCitation Excerpt :A multiplex detection for 26 bacterial species have been designed across 7 different genera, including Salmonella spp., Listeria monocytogenes., Vibrio spp., Shigella spp. Yersinia enterocolitica., Campylobacter spp. and diarrheagenic Escherichia coli [151]. Ligation based leaky surface acoustic wave (LSAW) biosensor was used in the A2293G SNP genotyping of the Japanese encephalitis virus [84].
The new frontier of diagnostics: Molecular assays and their role in infection prevention and control
2017, American Journal of Infection ControlCitation Excerpt :They can be PCR-based or oligonucleotide-based arrays. The potential for multiplexing of this technology is immense and has been used for simultaneous identification and/or genotyping of microbes.23-25 Any discussion regarding advances in clinical microbiology would be incomplete without mention of the matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF).
Multiplex Polymerase Chain Reaction Tests for Detection of Pathogens Associated with Gastroenteritis
2015, Clinics in Laboratory MedicineCitation Excerpt :Multiplex LDT for the detection of various bacterial enteric pathogens has been developed by various laboratories. A multiplex PCR/ligation detection reaction (LDR) assay was developed by Rundell and colleagues46 for the detection of bacterial pathogens from stool specimens. The panel targets 7 bacterial pathogens: Campylobacter spp, Vibrio spp, Shigella spp, Salmonella spp, L monocytogenes, Y enterocolitica, and diarrheagenic E coli.
Multiplex PCR: Aid to more-timely and directed therapeutic intervention for patients with infectious gastroenteritis
2022, Medicine (United States)
- ☆
Funding: This work was supported by Public Service grants UCI-AI062579 and U01-AI075470-01 from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. This work was also supported by Ruth L. Kirschstein National Service Award (NRSA) T32 Training Grant 5T32A1007613 from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.